MegaPro Biomedical Co

MegaPro Biomedical Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of MegaPro Biomedical Co (6827.TWO) as of Oct 16, 2026 is 97.30 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 87.88 % — a change of 10.72% (higher).

Cash Conversion

97.30 %

YoY

10.72%

Last updated:

Cash Conversion Rate (OCF/Net Income) of MegaPro Biomedical Co is 2025 97.30 % . Cash Conversion Rate (OCF/Net Income) of MegaPro Biomedical Co was 2024 87.88 % . It decreases by 10.72% higher compared to the previous year.

The MegaPro Biomedical Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
92.71 TWD
Jan 1, 2019
97.72 TWD
Jan 1, 2020
104.99 TWD
Jan 1, 2021
95.38 TWD
Jan 1, 2022
74.11 TWD
Jan 1, 2023
78.17 TWD
Jan 1, 2024
87.88 TWD
Jan 1, 2025
97.30 TWD
The MegaPro Biomedical Co Cash Conversion history
YEARCash ConversionYoY
97.30 %+10.72%
87.88 %+12.43%
78.17 %+5.47%
74.11 %-22.30%
95.38 %-9.16%
104.99 %+7.44%
97.72 %+5.40%
92.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MegaPro Biomedical Co Stock analysis

What does MegaPro Biomedical Co do? MegaPro Biomedical Co Ltd is a biotechnology company based in Zhubei, Taiwan, operating within the health care sector. The company has a workforce of 20 employees and completed its initial public offering (IPO) on October 19, 2021. Its primary focus is the development of drug ingredients utilizing nanoparticle and nanocell technology platforms. The company's product portfolio includes several compounds designated as MPB-1514, MPB-1523, MPB-1734, and MPB-2043. MPB-1514 is designed for intravenous treatment of anemia associated with chronic kidney disease. MPB-1523 is intended for intravenous diagnosis of hepatocellular carcinoma. MPB-1734 targets solid tumors through intravenous administration. MPB-2043 is used for intravenous diagnosis of metastases in peripheral lymph nodes near cancerous sites. The company maintains a website at https://www.megaprobio.com/ for further information. MegaPro Biomedical Co Ltd operates under the ticker symbol 6827.TWO and is registered with ISIN TW0006827009. It is headquartered in Zhubei, Hsinchu, Taiwan, and is engaged in the development of advanced biotechnological solutions for medical applications. MegaPro Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MegaPro Biomedical Co stock

Cash Conversion Rate (OCF/Net Income) of MegaPro Biomedical Co is 97.30 % in 2025.

Cash Conversion Rate (OCF/Net Income) of MegaPro Biomedical Co changed from 87.88 % to 97.30 %, representing a 10.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) MegaPro Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s MegaPro Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — MegaPro Biomedical Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — MegaPro Biomedical Co